Table 4. Factors associated with translation of oral tolerance to human disease.
| Dose |
| Immune marker of immunologic effect |
| Route (oral vs. nasal) |
| Mucosal adjuvant |
| Protein preparation |
| Combination therapy |
| Early therapy |
| Immunologic subgroups |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.